J Clin Psychopharmacol 2015 Jun;35(3):324-8
From the *Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine; †Community General Psychiatry Division, Johns Hopkins Bayview Medical Center; ‡Department of Medical Informatics, Kennedy Krieger Institute; §Department of Mental Health, Johns Hopkins Bloomberg School of Public Health; ∥Laboratory for Neurocognitive Imaging Research, Kennedy Krieger Institute, Baltimore, MD; ¶The Lewin Group, Falls Church VA; #School of Nursing, Johns Hopkins University; **Francis King Carey School of Law, University of Maryland; and ††Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
The assessment of adverse effects of psychiatric medications is important in clinical and research settings because they are often associated with medication discontinuation, symptom exacerbation, and reduced quality of life. Currently available assessment tools are either limited with regard to the number and variety of included adverse effects or are not practical for use in most clinical or research settings owing to specialized rater training required and administration length. This report describes a modification of the Monitoring of Side Effects Scale (MOSES), an established adverse effect rating scale, by adding severity anchors to improve its reliability and ease of use. Interrater reliability was good for 7 of the 8 bodily adverse effects assessed, with intraclass correlation coefficients ranging from 0.76 to 0.91 in a sample of patients with severe mental illness. This modified version of the Monitoring of Side Effects Scale holds promise as a useful tool for assessing medication adverse effects in clinical and research settings.